ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Aptose Biosciences Inc

Aptose Biosciences Inc (APTO)

0.22
0.0068
(3.19%)
Cerrado 11 Enero 3:00PM
0.22
0.00
(0.00%)
Fuera de horario: 6:53PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
0.22
Postura de Compra
0.219
Postura de Venta
0.22
Volume Operado de la Acción
1,760,193
0.2137 Rango del Día 0.23
0.13 Rango de 52 semanas 2.50
Capitalización de Mercado [m]
Precio Anterior
0.2132
Precio de Apertura
0.2275
Última hora de negociación
Volumen financiero
US$ 388,264
Precio Promedio Ponderado
0.22058
Volumen promedio (3 m)
7,330,732
Acciones en circulación
18,109,393
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.08
Beneficio por acción (BPA)
-2.83
turnover
-
Beneficio neto
-51.21M

Acerca de Aptose Biosciences Inc

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Mississauga, Ontario, Can
Fundado
-
Aptose Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker APTO. The last closing price for Aptose Biosciences was US$0.21. Over the last year, Aptose Biosciences shares have traded in a share price range of US$ 0.13 to US$ 2.50.

Aptose Biosciences currently has 18,109,393 shares in issue. The market capitalisation of Aptose Biosciences is US$3.86 million. Aptose Biosciences has a price to earnings ratio (PE ratio) of -0.08.

APTO Últimas noticias

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today...

Aptose Announces Positive Decision by Nasdaq Hearings Panel

SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant...

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML Populations, with Favorable SafetyTUS-based therapies are...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0184-7.718120805370.23840.2450.210713120600.2284896CS
40.02211.11111111110.1980.38950.17222366260.26297267CS
12-0.141-39.05817174520.3610.41620.1373307320.25731306CS
26-0.504-69.61325966850.7240.760.1335347770.26942057CS
52-2.26-91.12903225812.482.50.1318407970.29570339CS
156-20.78-98.95238095242123.250.137660642.68195425CS
260-89.78-99.755555555690138.78750.13105675743.48841833CS

APTO - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Aptose Biosciences?
El precio actual de las acciones de Aptose Biosciences es US$ 0.22
¿Cuántas acciones de Aptose Biosciences están en circulación?
Aptose Biosciences tiene 18,109,393 acciones en circulación
¿Cuál es la capitalización de mercado de Aptose Biosciences?
La capitalización de mercado de Aptose Biosciences es USD 3.86M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Aptose Biosciences?
Aptose Biosciences ha negociado en un rango de US$ 0.13 a US$ 2.50 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Aptose Biosciences?
El ratio precio/beneficio de Aptose Biosciences es -0.08
¿Cuál es la moneda de reporte de Aptose Biosciences?
Aptose Biosciences presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Aptose Biosciences?
El último beneficio anual de Aptose Biosciences es USD -51.21M
¿Cuál es la dirección registrada de Aptose Biosciences?
La dirección registrada de Aptose Biosciences es 5955 AIRPORT ROAD, MISSISSAUGA, ONTARIO, L4V 1R9
¿Cuál es la dirección del sitio web de Aptose Biosciences?
La dirección del sitio web de Aptose Biosciences es www.aptose.com
¿En qué sector industrial opera Aptose Biosciences?
Aptose Biosciences opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.83M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.72M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.61M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.69M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.83M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.31M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

APTO Discussion

Ver más
glenn1919 glenn1919 2 semanas hace
APTO..........https://stockcharts.com/h-sc/ui?s=APTO&p=W&b=5&g=0&id=p86431144783
👍️0
Scotty9 Scotty9 3 semanas hace
Looks like a I’m going to take a loss on this one
👍️0
Zeppo Zeppo 3 semanas hace
Okay, everyone. The company basically has three months to get its act together and retain its NASDAQ listing. No revenues are projected for 2025. These new collaborations are going to take time to develop. The last time the company had to scramble to retain its NASDAQ listing, what did it have to do? A reverse split. The company hasn't even been able to find its own way to Phase !!! testing with Tus....let alone Lux. So....what is it going to have to do again....unless its gets some blockbuster FDA news by March 31? Another reverse split. This day has been coming since the last reverse split was done.
👍️0
glenn1919 glenn1919 3 semanas hace
apto............................https://stockcharts.com/h-sc/ui?s=apto&p=W&b=5&g=0&id=p86431144783
👍️0
knrorrel knrorrel 3 semanas hace
https://ih.advfn.com/stock-market/NASDAQ/aptose-biosciences-APTO/stock-news/95133778/aptose-announces-positive-decision-by-nasdaq-heari
👍️0
knrorrel knrorrel 3 semanas hace
lol


sorry
👍️0
knrorrel knrorrel 3 semanas hace
lol - nice Post
👍️0
tw0122 tw0122 3 semanas hace
Nice making another round 
👍️0
Invest-in-America Invest-in-America 3 semanas hace
"EOIC", like at this link???
https://www.google.com/search?q=What+does+%22EOIC%22+mean+in+street+slang%3F&sca_esv=790e11adc1912a92&source=hp&ei=YJ1kZ8HrO-PbkPIPxKCYyAY&iflsig=AL9hbdgAAAAAZ2SrcT_uYmDaX2twpgyJ6L581HqdxC_A&ved=0ahUKEwjBm6ST8LSKAxXjLUQIHUQQBmkQ4dUDCBU&oq=What+does+%22EOIC%22+mean+in+street+slang%3F&gs_lp=Egdnd3Mtd2l6IiZXaGF0IGRvZXMgIkVPSUMiIG1lYW4gaW4gc3RyZWV0IHNsYW5nPzIHECEYoAEYCjIHECEYoAEYCjIHECEYoAEYCjIHECEYoAEYCkjywwJQAFi7dnAEeACQAQCYAeUBoAG1HKoBBzE2LjEzLjO4AQzIAQD4AQGYAiSgAssgwgIKEAAYgAQYRhj5AcICCBAAGIAEGLEDwgIFEAAYgATCAg4QABiABBixAxiDARiKBcICBxAAGIAEGArCAgwQABiABBgKGEYY-QHCAgcQABiABBgNwgIGEAAYFhgewgIIEAAYCBgNGB7CAgsQABiABBiGAxiKBcICCBAAGIAEGKIEwgIFECEYqwKYAwCSBwcxMy4yMC4zoAeN-wE&sclient=gws-wiz
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
Or, did you mean to type, "EPIC"????
👍️0
Invest-in-America Invest-in-America 3 semanas hace
APTO: No brainer here, K-N-R, in my STUPID opinion!!! (Heck, I just scalped a cheap Lotto Ticket [$1K] on @NVDI in the Post-M several minutes ago for $300 profit; 'small potatoes' for sure, but given this latest rage of JUST-RESCUED-FOR-CONTINUED-NASDAQ-LISTING late PR's, who can resist this stuff???!!!)
👍️ 1
knrorrel knrorrel 3 semanas hace
Sounds eoic
👍️0
knrorrel knrorrel 3 semanas hace
holy ahi_ ....coming Dollarland tomorrow ??
👍️0
Invest-in-America Invest-in-America 3 semanas hace
APTO: Flip-&-scalp these NASDAQ orphans all day long!!!
👍️0
Invest-in-America Invest-in-America 3 semanas hace
APTO: Back on the NASDAQ, a little more securely!!! (Another 10-bagger???)
👍️0
TheFinalCD TheFinalCD 3 semanas hace
https://x.com/AlertsAndNews/status/1869852144951799886
👍️0
Zeppo Zeppo 2 meses hace
Well....a Phase III push for Tus is on the back burner again. First the company decides to go it alone but can't decide on a dosage. Then it wants to partner with a 2nd party.......and now a 3rd. Comments, anyone?
👍️0
tw0122 tw0122 4 meses hace
In some .38s looks bottomy typical hedgie beat down bio
👍️0
Monksdream Monksdream 4 meses hace
APTO new 52=week low
👍️0
Monksdream Monksdream 4 meses hace
APTO new 52 week low
👍️0
Zeppo Zeppo 4 meses hace
Another reverse split seems inevitable. The cash infusion, hopefully, will hasten the company to eventually reach a Phase III status on Tusp sometime during my lifetime.
👍️0
Laster Laster 4 meses hace
Bought some AH Friday. What a huge mistake.
Looks like today it will retrace back to $0.50 or lower.
Oh well.
👍️0
glenn1919 glenn1919 4 meses hace
APTO.....................................https://stockcharts.com/h-sc/ui?s=APTO&p=W&b=5&g=0&id=p86431144783
👍️0
Imokhopeur Imokhopeur 5 meses hace
Buy
👍️0
Lilman72003 Lilman72003 5 meses hace
I’m in
👍️0
Monksdream Monksdream 5 meses hace
APTO new 52 week low
👍️0
Monksdream Monksdream 7 meses hace
APTO new 52 week low
👍️0
Zeppo Zeppo 7 meses hace
True to form, no revenue projections for the foreseeable future has relegated APTO to a pre-reverse split value of $.05.
👍️0
gp22 gp22 7 meses hace
PDYN : PallaDyne AI Corp: ,,,AI software for robotics...NVDA CEO discusses AI Robotics. PDYN

Low float , cash rich PDYN about to get found by AI crowd.

Huge ripper at anytime as they have been doing to many other quality unknown AI stocks

Link
https://stkt.co/AsMtZMIs
👍️0
Monksdream Monksdream 8 meses hace
APTO new 52 week low
👍️0
dcaf7 dcaf7 8 meses hace
Abstracts for EHA presentations are available. Title of one of two Tuspetinib abstracts is "SAFETY AND EFFICACY OF TUSPETINIB AS MONOTHERAPY ANDCOMBINED WITH VENETOCLAX IN A PHASE 1/2 TRIAL OF PATIENTS WITHRELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)". From the abstract: Objective responses were observed (overall CRc=16.9%) in pts receiving 80 mg TUS/400 mg VEN: FLT3-WT(n=49, CRc:14.3%), FLT3-MUT (n=15, CRc: 26.7%) including pts with prior FLT3i treatment (n=12, CRc=33.3%),prior VEN treated (n=48, CRc=16.7%), VEN-naïve (n=17, CRc= 17.6%), RAS-mutated (n=11, CRc=9.1%), andTP53 mutated (n=17, CRc=17.6%) pts. No objective responses were observed at 40mg TUS with VEN,indicating a dose-related response.
👍️0
dcaf7 dcaf7 9 meses hace
A new corporate presentation has been issued. It has updated clinical data with Tus/Ven doublet obtained in 60 evaluable patients. Previous analysis presented at ASH was done in 36 patients. Interesting, they show only waterfall plot on slide 16, no tables with all nuances. I manually counted all CRc there and ended up with number 11. So, it gives a CRc rate of 11/60, or 18%. In ASH presentation it was 9/36, or 25%. I think 18% is too low for evaluable population. Looks like Tus is not so powerful drug to be used as a single agent or in combination with Ven in R/R patients. Therefore, Aptose has no other choice but to run a triplet trial hoping for more favorable results.
👍️ 1
kojak007 kojak007 9 meses hace
Hi tartia. I sent you a message on the tcon board: Hi Tartia,
I have no idea how this is possible. I guess its dead now. What do you think?
👍️0
dcaf7 dcaf7 9 meses hace
20% probability of success
Published 03/27/2024, 05:28 PM
On Wednesday, Jones Trading adjusted its outlook on Aptose Biosciences (NASDAQ:APTO), lowering the price target to $5 from the previous $12, while maintaining a Buy rating on the company's stock. The adjustment comes as Aptose Biosciences shifts its development focus towards a new drug combination for treating Acute Myeloid Leukemia (AML).

The firm highlighted that Aptose's immediate strategy will concentrate on a triplet combination therapy involving tuspetinib, venetoclax, and HMA for first-line AML treatment. A pilot study for this combination is slated to begin in the summer, with initial findings expected to be presented at the American Society of Hematology (ASH) conference.

Meanwhile, the development for relapsed/refractory AML has been paused to improve strategic positioning, with data to be shared at the European Hematology Association (EHA) 2024 conference.

Jones Trading noted that if Aptose demonstrates clear clinical benefits in the first-line setting, it may lead to enhanced business development opportunities as compared to the relapsed/refractory AML setting. Still, the firm also pointed out that a capital overhang is a significant pressure point for both the stock and its clinical development progress.

The company's current cash position stands at $18.6 million, which is expected to fund operations through August 2024. Jones Trading has updated its financial model to reflect the new strategic direction towards first-line AML treatment, estimating unadjusted peak sales of approximately $250 million, assuming a 20% probability of success and a 40% market penetration among patients unfit for intensive chemotherapy.

In light of these developments and other minor changes across the model, Jones Trading reiterated its Buy rating but reduced the price target for Aptose Biosciences to $5. The firm believes that despite the lowered target, the company's stock remains a positive investment opportunity.
https://www.investing.com/news/company-news/aptose-biosciences-target-cut-maintains-buy-rating-on-new-drug-development-93CH-3355850
👍️0
Zeppo Zeppo 10 meses hace
Asking ourselves the obvious question, is APTO any closer to commercialization of product? My answer is NO, and I imagine yet another reverse split will be on the horizon in a year. Dilutions will take the stock below $1.00 again without any announcements of a stand-alone Phase 3 test anywhere......IMHO.
👍️0
dcaf7 dcaf7 10 meses hace
Not sure that increase in plasma concentration from 1 uM to 2-3 uM will help much. They don't report responses in 11 new AML patients they studied. Most disappointing is that they stopped developing Tus/Ven doublet as potentially registrational combination. They have good data with Flt3mut patients and now instead of working in this direction, they offer you to focus on triple combination project for which they don't have any preliminary data. A lousy strategy and Rice is a lousy leader.
👍️ 1
Tartiaboy Tartiaboy 10 meses hace
I was very happy to see that Lux is still alive. I don't think Aptose has the resources to develop it at this time. It's a shame. They really squandered this opportunity. In any event it is news that will keep my interest in Aptose alive. I haven't listened to the cc yet. They still have a huge $ problem and I think Hanmi is calling the shots.
👍️0
dcaf7 dcaf7 10 meses hace
Here is what Bejar said at ASH in December, “Brisk patient enrollment in our APTIVATE trial has led to a fast-growing database that includes many more patients at various stages of treatment. We look forward to reporting our next set of data in the first quarter of 2024.” I think, it should happen at earing call. Last chance to impress investors?
👍️0
Monksdream Monksdream 10 meses hace
APTO under $2
👍️0
Zardiw Zardiw 10 meses hace
$TCON Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
Tartiaboy Tartiaboy 10 meses hace
I still hold a speculative position in TCON. I am expecting binary news before EOM. Out of 46 pts. they had 4 responses by BICR and 7 by Investigator review. It is right on the edge of meeting the target. If met I see $1+ immediately, it not perhaps 10 cents immediately. If you want to discuss, let's do so on the Ihub TCON board.

I am watching a painful demise here for APTO.
👍️ 1
kojak007 kojak007 10 meses hace
Hi Tartia,
Are you still in TCON? I was thinking maybe they can actually indeed reach the 11.25% by BICR. Since beginning of 2023 thy are dosing with the double dose at 600. More data from that group could actually turn the needle. What do you think?
Greetings
👍️0
Monksdream Monksdream 10 meses hace
APTO new 52 week lo
👍️0
Tartiaboy Tartiaboy 10 meses hace
Unfortunately, I believe we have already seen a Hanmi takeover. They are just interested in TUS.
👍️0
spiderman3600 spiderman3600 10 meses hace
I think our only hope is a Hamni takeover.
👍️0
Zeppo Zeppo 10 meses hace
This is what happens after reverse splits when there is no perceived improvement to the business plan........let alone revenues
👍️0
Monksdream Monksdream 10 meses hace
APTO new 52 week low
👍️0
Tartiaboy Tartiaboy 11 meses hace
I have been rotating from APTO primarily into VINC over the past month. Also holding VSTM and ONCT.
👍️0
dcaf7 dcaf7 11 meses hace
Some thoughts on Rice.
Rice has an interesting career. “He served as Head of the Laboratory of Antiviral Drug Mechanisms and Manager of the HIV Clinical Interface Laboratory for the National Cancer Institute (NCI), National Institutes of Health from 1992 to 1998. In this position, Dr. Rice directed the activities of several projects targeting new ways to treat HIV and other infectious diseases. From 1989 to 1992, he was professor of Pediatric Hematology and Oncology at Emory University School of Medicine, where he built a program to identify new molecular structures as antiviral targets”. So, he was in hematology/oncology, but it was not related to oncology. Then, from Aug 1998 to Aug 2003 he worked as a CEO of Achillion Pharmaceuticals, an anti-infective pharmaceutical company. Under his leadership no drug was approved. From 2003 to 2013 he served as a CEO of Cylene Pharmaceuticals. The company was working on oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, or multiple myeloma. This drug is still in clinical trials, not even close to FDA approval. Their second drug was Quarfloxin, a selective binder for MYC GQ structure. Is it related to APTO-253? Anyway, later quarfloxin was discarded due to its poor bioavailability. Isn’t it a familiar theme? And from 2013 to the present, Rice has been a CEO of Lorus/Aptose Biosciences. The result of his work as a leader of Aptose is two failed drugs, APTO-253 and Luxeptinib. Point is that during his very long career in biotech industry as a CEO, Rice was not able to bring any drug to the market. I hope Tuspetinib is his last chance.
👍️0
dcaf7 dcaf7 11 meses hace
Would you like to share your greener pastures?
👍️0
Tartiaboy Tartiaboy 11 meses hace
Hello All. I have not posted here in a while but have continued to follow the discussions. As always, thank you Decaf for the information you share.

After serious deliberation I decided it was time to begin liquidating my APTO shares. I have been selling for the past month. There is no ONE reason. It is a cumulation of factors. I feel that Rice has lost his credibility and APTO will struggle for the foreseeable future. I will continue to monitor and may buy back shares at a later date.
On to greener pasteurs.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock